INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,570,672 | +208.1% | 84,718 | +83.8% | 0.00% | +300.0% |
| Q2 2023 | $509,866 | -83.9% | 46,100 | -80.4% | 0.00% | -88.9% |
| Q1 2023 | $3,159,958 | +143.5% | 235,291 | +124.3% | 0.01% | +125.0% |
| Q4 2022 | $1,297,786 | -78.2% | 104,914 | -75.5% | 0.00% | -80.0% |
| Q3 2022 | $5,963,000 | +111.5% | 427,436 | +109.4% | 0.02% | +122.2% |
| Q2 2022 | $2,819,000 | -66.4% | 204,154 | -60.4% | 0.01% | -64.0% |
| Q1 2022 | $8,386,000 | -4.7% | 515,449 | -4.5% | 0.02% | +31.6% |
| Q4 2021 | $8,796,000 | +31.3% | 539,951 | +19.7% | 0.02% | +26.7% |
| Q3 2021 | $6,701,000 | -24.1% | 451,218 | +2.0% | 0.02% | -25.0% |
| Q2 2021 | $8,832,000 | +213.6% | 442,245 | +262.5% | 0.02% | +185.7% |
| Q1 2021 | $2,816,000 | -58.9% | 122,013 | -56.0% | 0.01% | -65.0% |
| Q4 2020 | $6,851,000 | -23.5% | 277,386 | +28.5% | 0.02% | -37.5% |
| Q3 2020 | $8,951,000 | +420.1% | 215,906 | +501.2% | 0.03% | +255.6% |
| Q2 2020 | $1,721,000 | -91.8% | 35,913 | -89.2% | 0.01% | -94.7% |
| Q1 2020 | $20,974,000 | -43.8% | 333,127 | +10.6% | 0.17% | +52.7% |
| Q4 2019 | $37,330,000 | +104.4% | 301,246 | +9.5% | 0.11% | +83.6% |
| Q3 2019 | $18,260,000 | -49.7% | 275,165 | -39.7% | 0.06% | -50.0% |
| Q2 2019 | $36,330,000 | +26.1% | 456,576 | +77.2% | 0.12% | +31.2% |
| Q1 2019 | $28,816,000 | -7.8% | 257,606 | -17.0% | 0.09% | -23.8% |
| Q4 2018 | $31,264,000 | +8.7% | 310,187 | +36.3% | 0.12% | +54.4% |
| Q3 2018 | $28,761,000 | +948.9% | 227,616 | +596.6% | 0.08% | +887.5% |
| Q2 2018 | $2,742,000 | -54.1% | 32,675 | -68.1% | 0.01% | -57.9% |
| Q4 2017 | $5,979,000 | +59.3% | 102,348 | +230.2% | 0.02% | +46.2% |
| Q2 2017 | $3,753,000 | +730.3% | 31,000 | +675.0% | 0.01% | +550.0% |
| Q1 2017 | $452,000 | -82.6% | 4,000 | -74.7% | 0.00% | -80.0% |
| Q3 2016 | $2,601,000 | +128.0% | 15,800 | +97.5% | 0.01% | +100.0% |
| Q2 2016 | $1,141,000 | -86.3% | 8,000 | -77.3% | 0.01% | -86.5% |
| Q3 2014 | $8,355,000 | +186.0% | 35,299 | +186.0% | 0.04% | +184.6% |
| Q2 2014 | $2,921,000 | +943.2% | 12,344 | +201.1% | 0.01% | +550.0% |
| Q4 2013 | $280,000 | – | 4,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |